Scarica l'app Stockscreener
24.55
2.67%
0.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$23.89
Aprire:
$23.92
Volume 24 ore:
1.38M
Relative Volume:
0.71
Capitalizzazione di mercato:
$4.06B
Reddito:
-
Utile/perdita netta:
$-451.71M
Rapporto P/E:
-7.6098
EPS:
-3.2261
Flusso di cassa netto:
$-462.19M
1 W Prestazione:
+3.32%
1M Prestazione:
+20.65%
6M Prestazione:
+36.26%
1 anno Prestazione:
+165.45%
Intervallo 1D:
$23.70
$24.87
Intervallo di 1 settimana:
$21.71
$24.87
Portata 52W:
$8.88
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
24.55 | 3.95B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
480.00 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
665.67 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.09 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.74 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
275.34 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Iniziato | Bernstein | Mkt Perform |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
DYN Initiated Coverage On by Cantor Fitzgerald -- Rating Set to Overweight - GuruFocus
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway - The Globe and Mail
Dyne Therapeutics closes $431.4 million stock offering - Investing.com
Dyne Therapeutics closes $431.4 million stock offering By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Closing of Upsized Public - GlobeNewswire
Dyne a new overweight at Cantor on platform for neuromuscular disorders - Seeking Alpha
Cantor Fitzgerald initiates Dyne Therapeutics stock with overweight rating By Investing.com - Investing.com Canada
Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling? - Yahoo Finance
Form 424B5 Dyne Therapeutics Inc For: 22 July By Investing.com - Investing.com South Africa
Dyne Therapeutics Launches 18.3M-Share Offering at $20.50; Nets ~$352M, Greenshoe to $405M - TradingView
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) - MSN
Why Dyne Therapeutics (DYN) Stock Is Down Today - Moomoo
Dyne Therapeutics (DYN) Upsizes Public Offering to $375.15M Amid Stock Decline - GuruFocus
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - The Globe and Mail
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Why is Dyne Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Dyne Therapeutics stock falls 9% after pricing stock offering By Investing.com - Investing.com Australia
Dyne Therapeutics stock falls 9% after pricing stock offering - Investing.com UK
Dyne Therapeutics Prices Upsized $375.2 Million Secondary Offering - marketscreener.com
Form 424B5 Dyne Therapeutics Inc For: 21 July By Investing.com - Investing.com South Africa
Dyne Therapeutics Stock Tumbles After Hours: Here's Why - Benzinga
Form 424B5 Dyne Therapeutics Inc For: 21 July - Investing.com India
DYN: Increased Offering Size and Pricing Range Announced - GuruFocus
Dyne Therapeutics prices $375 million stock offering - Investing.com
Dyne Therapeutics prices $375 million stock offering By Investing.com - Investing.com South Africa
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock - The Manila Times
Dyne Therapeutics prices $375M upsized public o... - Pluang
Dyne Therapeutics,Announces Pricing Of Upsized Offering Of 18.3 Million Shares At $20.50 Per Share - TradingView
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock - GlobeNewswire Inc.
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits
Stocks to Watch: Super Micro Computer, AAR, Pegasystems, Dyne Therapeutics, Weatherford - Moomoo
Shares of Dyne Therapeutics Slide on $300M Stock Offering - Moomoo
Dyne Therapeutics Launches $300 Million Common Stock Offering - Moomoo
Dyne Therapeutics launches $300 million stock offering By Investing.com - Investing.com Nigeria
Dyne Therapeutics launches $300 million stock offering - Investing.com India
Dyne Therapeutics stock falls on $300M equity offering - Investing.com
Dyne Therapeutics Announces Proposed Public Offering of Common Stock - The Manila Times
Dyne Therapeutics stock falls on $300M equity offering By Investing.com - Investing.com Nigeria
Dyne Therapeutics Announces $300 Million Proposed Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics Announces Proposed Public Offering Of Common Stock - TradingView
Press Release: Dyne Therapeutics Announces Proposed Public Offering of Common Stock - Moomoo
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dyne Therapeutics Inc Azioni (DYN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rhodes Jason P | Director |
Jul 07 '26 |
Sale |
23.26 |
297,211 |
6,913,822 |
2,962 |
0.31%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):